New drug combo takes aim at rare sarcoma
NCT ID NCT07460986
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called bexmarilimab (an antibody) combined with the chemotherapy doxorubicin in people with metastatic soft-tissue sarcoma. The trial has two parts: first, finding the safest dose, then checking if the combination helps slow the cancer. About 278 adults who have not had doxorubicin before will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bexmarilimab (an experimental antibody) plus doxorubicin (chemotherapy)
- What this could lead to
- If it works, this combination could offer a new treatment option for people with advanced soft-tissue sarcoma, potentially slowing the cancer's growth.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so the benefits are uncertain. The combination may cause serious side effects, and it's not yet known if it works better than standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA OF SOFT TISSUE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.